• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Cannabis

The Cannabis Sector and Its Dot-Com Like Meltdown

Black-market vaping has made the entire cannabis group toxic.
By TIMOTHY COLLINS
Sep 30, 2019 | 03:30 PM EDT
Stocks quotes in this article: MO

The unintended consequence in the slow-moving argument around cannabis and CBD legalization is the rise in lung illnesses and deaths among vapers. I have been a supporter of the cannabis and CBD market and many companies within them, but with the rising risks of black-market vaping, the entire sector has become toxic.

The irony is these are the companies doing "wrong." I'm not defending Juul here or even Altria (MO) . A company that makes a Fruity Pebbles-flavored alt-nicotine vape product isn't targeting adults. Let's be honest here.

And, yes, there are personal feelings involved in this topic. While I believe cannabis, hemp, and cannabinoids have a ton of potential positive uses, I'm not a fan of vaping, regulated or not. The taking of anything directly into the lungs that isn't medically prescribed and fully tested scares me.

I understand the upside that smoking/vaping provides in terms of measured delivery and quick uptake/effectiveness, but as alternative delivery methods continue to improve, that gap is closing.

The biggest problem I see is the government. We are not only talking about the government dragging its feet on approval and subsequent regulation but also now financing and taxation.

Cannabis and cannabis-related companies are faced with a high cost of capital to do business. That cost of capital is eventually passed through to the consumer. Additionally, companies pay an enormous amount in taxes. Again, this is passed through to the consumer if the business wants to remain in business.

Unfortunately, some users are looking for the lowest cost, which pushes them to the black market. Some users don't have legal access, which pushes them to the black market.

And the black market sells products with the largest "profit" margins looking to stretch every dollar because of the heightened risk, which pushes some sellers to the use of untested and potentially dangerous substances.

We are not seeing deaths from regulated products in regulated markets. We are seeing deaths, in my view, as a result government entities afraid to act for fear of seeing deaths or epidemic usage growing out of control. The irony is by not acting because of their fears, their fears are coming to fruition.

From the rubble will rise some fantastic opportunities in quality names, but the cannabis sector drubbing right now is reminiscent of the dot-com blowup. With depressed stock prices and valuations falling in the private market, we are going to see some names vanish or bought at a cheap price for fear they won't get through this vaping disaster.

More government is seldom the answer, but no government or one turning a blind eye can be even worse.

I know a few subs have asked me about specific names and their poor performance as of late, but what we are seeing now is not company-specific weakness. This action is what we call "throwing out the baby with the bathwater." Everything is being sold whether the underlying company performance is strong or weak.

If you don't have patience or you've been buying every name because cannabis 2.0 will reignite the sector this month, then the road may be rough until the black-market vaping issue is directly addressed.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins had no positions in any securities mentioned.

TAGS: Mergers and Acquisitions | Regulation | Investing | Trading | Marijuana | Tobacco | Cannabis

More from Cannabis

Cannabis Stocks Are Too High

Ed Ponsi
Sep 19, 2023 10:20 AM EDT

The U.S. Department of Health has announced that it favors reclassifying marijuana, but traders would do well not to be sucked in by the recent surge in cannabis names.

As Tilray Gets a Retail Cheer, Its Stock Could Still Be Toast

Ed Ponsi
Aug 15, 2023 9:45 AM EDT

TLRY bought eight beer brands from Anheuser-Busch InBev, boosting its 'meme' stock potential.

Want to Invest in Constellation Brands? Wait for a Discount

Stephen Guilfoyle
Apr 6, 2023 11:10 AM EDT

The quarter wasn't great, but the guidance was promising.

Doug Kass: Cannabis Stocks Are Still Not SAFE

Doug Kass
Dec 20, 2022 11:15 AM EST

Though it is tempting, there are a host of reasons why I'm not bottom fishing.

Cannabis ETFs Could Soon Turn a New Leaf

Mark Abssy
Dec 8, 2022 1:11 PM EST

With likely passage of new legislation, the pot industry might have a remedy for the nausea it gave investors.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:20 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading in Multiple Time Frames
  • 10:24 AM EDT BRUCE KAMICH

    This Could Get Messy

    A number of key stocks are getting close to import...
  • 01:41 PM EDT CHRIS VERSACE

    Latest AAP Podcast With Helene Meisler!

    Listen in as the Action Alerts PLUS podcast talks ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login